News and Research
2016: Fibrosis/Cirrhosis/Liver Cancer/Transplants
Nov 18, 2016
AASLD 2016 Review - Watch Advances in Chronic Hepatitis C: Management and Treatment
The review and discussion will focus on HCV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations; therapies in development; epidemiology; and diagnosis and clinical management of specific patient populations, including HCV/HIV co-infected and cirrhotic patients.
Liver Fibrosis: Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko
Nitto’s lead product, ND-L02-s0201, is a targeted siRNA therapy that is designed to inhibit HSP47, a collagen specific chaperone which regulates collagen synthesis and secretion, and prevent further collagen deposition as well as enable resolution of existing fibrosis. Nitto is currently conducting a 5-week open-label Phase 1b study in patients with advanced fibrosis (F3-F4c) due to NASH or hepatitis C. The U.S. Food and Drug Administration granted fast track designation to ND-L02-s0201 for two indications, liver fibrosis and cirrhosis secondary to NASH and liver fibrosis and cirrhosis secondary to HCV.
Coffee Consumption and Herbal Tea Tied to Lower Liver Stiffness
Herbal tea and coffee might protect the liver among healthy adults, according to findings presented at The Liver Meeting® 2016.
MRE, MRI-PDFF best other techniques for detection of fibrosis, steatosis
Recent findings show magnetic resonance elastography was more accurate for detecting liver fibrosis vs. transient elastography, and MRI-based proton density fat fraction was more accurate than controlled attenuation parameter for detecting steatosis, in patients with biopsy-proven nonalcoholic fatty liver disease.
October Issue Clinical Liver Disease
Liver fibrosis: Which mechanisms matter?
Noninvasive liver fibrosis scores lack accuracy in some patient groups
With Hepatitis C and non-alcoholic fatty liver disease being a healthcare issue of significant proportions to baby boomers, the availability of noninvasive tests to evaluate the degree of liver injury has become quite commonplace. But how accurate are these tests? Liver enzymes are notoriously inaccurate at determining the degree of either injury or scarring. Liver biopsy is the gold standard, but not without risk and it is certainly somewhat invasive. A study that evaluated the use of three noninvasive fibrosis scores in non-alcoholic fatty liver disease showed they had low accuracy in certain populations, researchers reported in The American Journal of Gastroenterology. The study analyzed aminotransferase/alanine transaminase ratio, Fibrosis-4 score and NAFLD fibrosis score. Read the article here
Commentary @ Healio Noninvasive tests inaccurate for younger, elderly patients with NAFLD
The aminotransferase/alanine transaminase ratio, NAFLD fibrosis score and Fibrosis-4 score yielded poor accuracy in specificity for advanced fibrosis in adults
Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods
Technique May Identify Patients with Fast-Progressing Fibrosis in Nonalcoholic Fatty Liver Disease
Liver fibrosis linked to blood microbiota in obesity
Blood microbiota dysbiosis and liver fibrosis existed concomitantly in patients with obesity, according to published findings. “We have shown in an extensively…
Full Text @NATAP
CDC - 23-27% with HCV Have Advanced Fibrosis or Cirrhosis - The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States
Pilot Study to Evaluate Metformin Impact on Liver Fibrosis in Hepatitis C-HIV Coinfection
... prevent progression or promote regression of liver fibrosis in hepatitis C virus ... HCV which could improve therapy outcomes for liver and metabolic disease, ...
Permanent Liver Damage May Be Avoided with Early Hepatitis C ...
In a study published in PLOS One, hepatitis C virus (HCV) patients saw a decrease in liver stiffness (LS) from pre-treatment to sustained virological response at 24 weeks (SVR24), and no significant decrease during the additional follow-up.
The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States.
Study finds clues to fibrosis progression in chronic HCV infection
Fibrosis progression in hepatitis C virus–infected individuals is not linear, is associated with alanine aminotransferase–related flares, and varies according to stage, with those who are least fibrotic tending to have the highest progression, according to a study.
ARFI elastography predicts fibrosis in patients with HCV who achieved SVR
The Burden of Hepatitis C Infection–Related Liver Fibrosis in the United States
Testing from a large US commercial laboratory indicates that about 1 in 4 HCV-infected persons have levels of liver disease put them at highest risk for complications and could benefit from immediate antiviral therapy.
Let-7 miRNA associated with hepatic fibrosis progression in chronic HCV
New medication shows promise against liver fibrosis in animal studies
HIV increases risk for liver fibrosis
In a case-control study, Asian patients with HIV without hepatitis B or C virus infection showed high rates of liver fibrosis and fatty liver compared with patients without HIV.
CROI 2016: Viral Hepatitis and Liver Fibrosis.
Premature menopause increases risk for higher severity fibrosis among women with NAFLD
Fibrosis in HCV genotype 3 progresses with age
Evidence of fibrosis was common in older patients with hepatitis C virus genotype 3 infection, indicating fibrosis progresses with age ..
Behind the Headlines - 'Friendly' virus repairs damaged liver cells (but only in mice)
Researchers were able to improve liver damage in mice, but this does not amount to curing an addiction to alcohol.
Researcher calls hepatic fibrosis ‘a translational success story’
Basic science discoveries in the last three decades have made fibrosis one of the most dynamic frontiers in liver disease, according to Scott L. Friedman, MD, dean for therapeutic discovery and chief of the division of liver diseases at the Icahn School of Medicine at Mount Sinai Hospital, New York, NY.
The March Toward Elastography for Assessing Fibrosis in HCV
Liver Fibrosis Decreases Cognitive Function in Women, Independent of HIV or HCV
Promising new blood test is first of its kind to detect liver scarring
April 5 2016
Novel 3-D imaging offers new tool for identifying advanced fibrosis in liver
Researchers have conducted a prospective study of 100 patients (56 percent women) with biopsy-proven NAFLD to assess the efficacy of two-dimensional magnetic resonance elastography (MRE) and a novel 3-D version.
Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity
Liver fibrosis is a wound-healing response characterized by the accumulation of extracellular matrix (ECM) following liver injury such as hepatitis C, hepatitis B, excess alcohol consumption and nonalcoholic fatty liver disease (NAFLD)
Liver fibrosis decreases cognitive function in women, independent of HIV or HCV
Nimbus Granted Fast Track Designation for NDI-010976, for the Treatment of NASH
Earlier HCV Treatment Improves Cost Effectiveness of Care
Treating hepatitis C virus (HCV) infection at early stages of fibrosis not only improves health outcomes but is cost-effective, according to a new study.
Aspirin lowers indices in liver fibrosis, may reduce CLD
In a cross-sectional analysis, researchers found aspirin use was associated with decreased indices for liver fibrosis, suggesting aspirin can reduce further liver injury and chronic liver disease, according to published findings.
Gilead/FDA Grants Priority Review for Sofosbuvir/Velpatasvir - To Treat HCV Genotype 1-6
Hepatic Fibrosis Has Strong Genetic Component
rs from the University of California, San Diego evaluated 60 pairs of adult twin participants using liver MRIs between January 2012 and January 2015 in order to investigate the heritability of hepatic fibrosis.
Improved Fibrosis Staging in Patients With Liver Disease
Liver International, December 23, 2015
Sustained SVR With Sofosbuvir-Based Regimens in Chronic HCV With Cirrhosis Confirmed
"Preliminary data from this ongoing observational study of SOF-treated patients with cirrhosis who have achieved SVR show SVR maintained in >99% of patients with a median follow-up of 21 months from the end of treatment," reported Andrew J. Muir, MD, of Duke University in Durham, NC.
Large Study Identifies Increase of Cirrhosis in Hepatitis C Patients
BOSTON, Nov. 11, 2016 /PRNewswire/ -- Over the past decade, the prevalence of cirrhosis has increased by almost 40 percent among people with hepatitis C (HCV) in the United States, according to research presented at The Liver Meeting® - held by the American Association for the Study of Liver Diseases.
Noninvasive tests predict portal hypertension, varices in cirrhosis
Recent findings suggest noninvasive tests can be used to identify patients with compensated liver disease at high risk for clinically significant portal hypertension and varices needing treatment.
Delayed HBV, HCV diagnosis may increase advanced liver disease
Despite rates of hepatitis B- and hepatitis C-related cirrhosis and hepatocellular carcinoma declining over the years in New South Wales, Australia, researchers insist that delayed infection notification can lead to increased risk for advanced liver disease and hepatitis screening efforts should be enforced for prevention purposes, per published findings.
When Hepatitis C Treatment Isn’t Enough
A look at hepatitis C and risk of cirrhosis and liver cancer.
Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study
Investigational HCV drug combo yields high SVR12 rates in compensated cirrhosis
A once-daily regimen of two investigational, direct-acting anti-HCV agents, ABT-493 and ABT-530, was well tolerated and...
High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients
Multispecies probiotic may improve liver function for patients with cirrhosis
A probiotic, bacteria-based powder may preserve and increase liver function by enhancing serum neopterin levels and neutrophils' production ...
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
In this prospective study patients with cirrhosis treated with interferon-based therapy or interferon-free regimens who achieved sustained virologic response (SVR) reduced; overall mortality and risk of death from liver-related and non–liver-related causes.......
Liver Stiffness Measurement and Outcome in Patients With HCV
Liver stiffness measurement is not a surrogate of disease progression of HCV patients with cirrhosis. HCV patients with cirrhosis should undergo the recommended follow-up, regardless of liver stiffness measurement.
Light-to-moderate alcohol intake increases risk of HCC in patients with HCV-related cirrhosis
Full text - Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study
NEJM - Treatment of Patients with Cirrhosis
This guide to the practical treatment of patients with cirrhosis summarizes recent developments. It includes advice on medical management, invasive procedures, nutrition, prevention, and strategies to protect the cirrhotic liver from harm.
Epilepsy linked to hepatic encephalopathy in patients with cirrhosis
HCV eradication does not impact systemic inflammation in cirrhosis
Bone Marrow Stem Cells and its Niche Components are Adversely Affected in Advanced Cirrhosis of Liver
Bone marrow (BM) is reservoir for immune and hematopoietic cells and is critical for tissue repair and regeneration. All these functions are severely altered in cirrhosis.
Do Nonselective Beta Blockers Increase Mortality in Patients With Cirrhosis and Ascites?
Diabetes Mellitus in Patients With Cirrhosis
Liver International, July 19, 2016
DAAs may benefit in long term for patients with decompensation
The use of direct-acting antivirals as therapy for patients with hepatitis C virus infection and decompensated cirrhosis may lead to long-term improvement in liver…
Three Complications of Cirrhosis: Dr. Rashid Khan Explains Further
Stages of Liver Cirrhosis
Statins reduce the risk of cirrhosis in Hep B patients
Hepatitis C: Once the viral infection has healed, high-risk portal vein hypertension also diminishes
This not only improves their prognosis but is also a relief for patients, because it means they can stop taking medications to prevent the complications of liver cirrhosis and therefore no longer have to put up with their side-effects.
Can Blood Levels of Ammonia Predict Risk and Frequency of Hepatic Encephalopathy in Patients With Cirrhosis?
Only treating patients with cirrhosis with DAAs will have limited impact on HCV epidemic in England
Treatment of Chronic Hepatitis C in Patients With Cirrhosis
What is the safest and most effective way to treat patients with chronic hepatitis C with cirrhosis?
New Hep C Recs Target Unique Populations
Updated guidelines from the AASLD and IDSA for the treatment of HCV have identified ...The guidelines for decompensated cirrhosis recommend direct-acting antiviral agents for patients with HCV genotypes 1, 2, 3 and 4...
HCV-related cirrhosis prevalence increases over time
The rate of cirrhosis found among patients with hepatitis C virus infection increased over time, including individuals who were unaware they had hepatitis C, according…
AbbVie Receives NDA for Viekira Pak/HCV genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
Successful antiviral treatment for hepatitis C associated with reduction in risk of cirrhosis, HCC and overall mortality, regardless of age.
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population
Case Studies in Personalizing All-Oral Therapy for HCV in Patients With Cirrhosis
In this Interactive Case Challenge, Paul Y. Kwo, MD, explores important considerations when selecting all-oral HCV therapy for patients with cirrhosis.
Hepatitis C Treatment and Cirrhosis
Nutritional therapy may slow down cirrhosis | Atlas of Science
Serum Level of Thyroid Hormones in Patients with Chronic Hepatitis C Virus Infection
Thyroid profile abnormalities were seen in cirrhotic HCV patients when compared to non-cirrhotic patients. The abnormalities in the serum level of THs (decreased FT3, FT4, and increased TSH) are strongly associated with the severity of liver damage and advancing of the child score.
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease
There are extensive data from phase III or IV studies on the efficacy of IFN-free regimens, but patients with compensated and decompensated cirrhosis were often underrepresented. Currently, more data are emerging from real-world studies on the efficacy of these regimens, which included patients with the most severe cirrhosis. Table 1–Table 4 show the data from phase III or IV studies available on the efficacy of IFN-free antiviral therapy. Here we will discuss the treatment regimens in a more conceptual way for the treatment of patients with compensated cirrhosis.
SVR leads to decreased spleen size in patients with HCV, cirrhosis
Researchers observed a decrease in spleen size over time after patients with hepatitis C virus infection and cirrhosis achieved successful sustained virologic response…
HCV Advocate Eblast: March, 2016
Hepatitis C Treatment and Cirrhosis – Lucinda discusses the importance of treating people with cirrhosis in this timely article to coincide with the FDA approval of the new indications for Harvoni.
The Prevalence of Cirrhosis in Patients with Hepatitis C Is Growing
Predicting the Development of Liver Cirrhosis by Simple Modelling in Patients With Chronic Hepatitis C
Ledipasvir/sofosbuvir for Cirrhotic Patients With Chronic HCV
FDA Hepatitis Update -Important changes to Harvoni affecting several categories of patients
On February 12, 2016, the FDA approved changes to the Harvoni (ledipasvir and sofosbuvir) fixed-dose combination label to expand the patient population to include those with chronic hepatitis C virus genotype 1, infection who are liver transplant recipients, genotype 4 infection who are liver transplant recipients without cirrhosis, or with compensated cirrhosis, and genotype 1 infection with decompensated cirrhosis.
Drinking coffee may reduce the risk of liver cirrhosis
Regular consumption of coffee was linked with a reduced risk of liver cirrhosis in a review of relevant studies published before July 2015.
Researchers find statin use lowered decompensation, death in HCV
Healio - Jan 28, 2016
In a retrospective cohort study using data from the Veteran Affairs Clinical Case Registry, patients with hepatitis C virus infection and compensated cirrhosis who used statins had a lower risk for cirrhosis decompensation and mortality vs. nonstatin ...
Insomnia, Muscle Cramps, Fatigue, Itching In Cirrhotic Patients
Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection
Nutritional assessment in cirrhotic patients with hepatic encephalopathy
Nutrition status is directly associated with survival of cirrhotic patients. Although there are many studies focusing on the nutrition role in cirrhosis, this article specifically aimed to discuss practical nutritional strategies that can be applied to evaluate the body composition of
Hepatic encephalopathy patients.
U.S. FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Virus Patients with Compensated Cirrhosis
The current dosing recommendation for patients with GT1b and compensated cirrhosis is to administer RBV with VIEKIRA PAK for 12 weeks.
Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
Patients infected with HCV genotypes 1-6 and decompensated cirrhosis were randomly assigned to treatment with sofosbuvir–velpatasvir for 12 weeks, sofosbuvir–velpatasvir plus ribavirin for 12 weeks, or sofosbuvir–velpatasvir for 24 weeks.
Occult HCV May Persist in Treated Patients After Liver Transplant
Despite a sustained virologic response for 12 weeks (SVR12) to direct-acting antiviral agents for recurrent hepatitis C virus (HCV) infection following liver transplantation, some patients continue to have occult infection.
Optimal MELD Threshold for HCV Tx Pre-Liver Transplant 23 to 27
(HealthDay News) -- For hepatitis C virus (HCV) patients with decompensated cirrhosis who are eligible for liver transplant (LT), the optimal model for end-stage liver disease (MELD) threshold below which they should receive HCV treatment is 23 to 27, according to a study published online Nov. 5 in Hepatology.
Timing for HCV Therapy in Liver Transplantation
Alimentary Pharmacology & Therapeutics, November 22, 2016
Wait-listing for liver transplantation decreasing in the DAA era
BOSTON — Wait-listing for liver transplantation among decompensated cirrhotics decreased by approximately 30% between the interferon and…
Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection
NASH surpasses HCV as top etiology for adults listed for liver transplant
Read the Perspective from Dina Halegoua-De Marzio, MDLAS VEGAS — Nonalcoholic steatohepatitis is the number one etiology of liver disease among adults under the age of 50 years listed for liver transplantation, surpassing hepatitis C virus infection, according to findings presented at ACG 2016.
Coffee delays liver disease progression, extends survival post-LT
Drinking at least 200 mL coffee a day may stave off the advancement of alcoholic liver disease and some cases of primary sclerosing cholangitis in…
Many liver transplant candidates have deficits in physical activity that are missed by clinicians
Hep C virus RNA persists in liver explants awaiting liver transplantation
October's issue of Gastroenterology reports that hepatitis C Virus RNA persists in liver explants of most patients awaiting liver transplantation treated with an interferon-free regimen.
UK patients who have liver transplants abroad get poorer management
Organ Transplants Linked to Higher Skin Cancer Risk
Experts say all recipients should have full-body skin evaluations after transplant surgery
Sovaldi shows high SVR12 in patients with HCV after transplant
Sovaldi-based combination therapies led to 12-week sustained virologic response in nearly 93% of patients who were reinfected with hepatitis C virus and had severe fibrosis after receiving a liver transplant, according to findings published in Liver Transplantation
Link To: The Current treatment recommendations in HCV liver transplant recipients
The patient perspective: Waiting for the liver
Vladimir and Estragon, both afflicted with chronic hepatitis C, met while attending support group and became companions engaged in endless conversation concerning their plight. The two were listed. … and, waited for the liver that had not come today but surely would tomorrow. Then, in the midst of the waiting – something changed, dramatically!
Patients with HCC more likely to be placed on liver transplant waitlists
Those With Liver Transplants Have Excellent Chance of Hepatitis C Cure
Health care system distrust does not affect liver transplant listing
Factors that influence access to liver transplantation and organ donation
Surviving a Liver Transplant
Now that I’ve had my first anniversary with my new liver, it’s probably safe to say that I am surviving a liver transplant. That first year is a little iffy, what with...
Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality
The imbalance between the increasing number of candidates for LT and the limited and unchanged pool of donors makes it critical to establish a prioritization system that ensures an optimized allocation policy
Colton Cooper shares his inspirational story about his third liver transplant.
#3LiverTransplants: First Recovery (Part 1)
Although I had a fresh ten-inch scar across my chest, multiple IV lines running through my veins, taking a ton of medicines that I can’t pronounce and stuck lying in a hospital bed, I felt healthier than I had been in a very long time.
Study Suggests Federal Standard May Be Thwarting Some Transplant Patients
When You Don’t Look Sick with Hepatitis C: how to
From the age of 30 on I was telling my doctors that my food didn’t metabolize well, my body ached, there was dizziness, fatigue, and a bunch of other symptoms. I honestly felt like a hypochondriac some of the time. They kept prescribing antidepressants, sleep aids, and pain pills.
DELISTING OF LIVER TRANSPLANT CANDIDATES WITH CHRNIC HEPATITIC C AFTER VIRAL ERADICATION: A EUROPEAN STUDY
Pediatric LT recipients show increased odds for survival post-transplant
April 28, 2016
BARCELONA — Children who underwent liver transplantation lived for 20 years or more post-transplant, according to data presented at the International Liver…
Hepatitis C in Limelight Again at Liver Congress
Other hepatitis C trials will address regimens for difficult-to-treat patients, such as those infected with genotype 3, transplant patients, and patients who failed previous treatment with a direct-acting antiviral. There will also be discussions on post-treatment monitoring for patients with hepatitis B or hepatitis C, who could still be at risk for hepatocellular carcinoma.
Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation
Hepatitis C Treatment Helps Reduce Need for Liver Transplant
Geographic Access Issues with Liver Transplantation
The MELD (Model for End-stage Liver Disease) scoring system was developed to decrease access disparity for patients who need a liver transplant. Despite its implementation, large geographic disparities exist in the likelihood of either being removed from the transplant list due to progressive disease or actually receiving a transplant.
Nanotechnology a 'green' approach to treating liver cancer
November Updates - Liver Cancer After Treatment For Hepatitis C
Research demonstrates that while SVR markedly reduced liver-related complications and liver cancer, some long-term risk for liver cancer remained in those who were cured of Hepatitis C. But after direct-acting antiviral therapy does the risk of developing liver cancer increase? Today we look at two studies on the subject presented recently at The Liver Meeting® 2016, along with research presented in April at the International Liver Congress 2016.
Regorafenib Renews Hope in Hepatocellular Carcinoma
After numerous failed attempts to uncover an effective second-line systemic therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib, optimism was fading in the industry; however, that all changed with regorafenib (Stivarga), a novel second-line agent that is currently being considered for approval by the FDA, said Jordi Bruix, MD, at the 2016 AASLD Liver Meeting.
AASLD 2016 Liver Cancer Rare After HCV Therapy
The risk of liver cancer in the first year after such therapy was pretty much the same as it is in untreated patients, according to Alfredo Alberti, MD, of the University of Padua in Italy. On the other hand, the rare patients who developed cancer after HCV treatment were more likely to have an aggressive form of the disease, Alberti told reporters at the American Association for the Study of Liver Diseases (AASLD) annual meeting.
AASLD 2016 Dr. George N. Ioannou on the Efficacy of Antiviral Agents for Hepatitis C in HCC Patients
AASLD 2016 Dr. Gonzalez on Cost-Benefit of Treating Hepatitis C in HCC Patients Before Transplant
First Oral Pentamidine Isethionate Safe, Well Tolerated for Early Stage HCC
The investigational oral pentamidine isethionate formulation VLX103 is safe and well tolerated at the once-daily 300mg to 900 mg dose.
AASLD 2016 - Is There an Increased Risk of Cancer After Taking Direct-Acting Antiviral Medication?
BOSTON, Nov. 11, 2016 /PRNewswire/ -- A new study presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases — found patients with hepatitis C who take direct-acting antiviral medication are at no higher risk for developing liver cancer than those who do not take the medication. However, they might be at an increased for more aggressive, infiltrative patterns of cancer, should they develop it.
AASLD 2016 - Number of Hepatitis B-Related Liver Transplants Drops While Hepatitis B-Related Liver Cancer Continues to Rise
BOSTON, Nov. 11, 2016 /PRNewswire/ -- Research presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – shows a recent plateau of chronic hepatitis B patients listed for liver transplantation, but a continued rise in liver cancer among these patients.
Guide to the Management of Patients With Advanced HCC
Download this at-a-glance resource for a brief summary of staging and treatment selection, systemic therapy approaches and toxicity management, and emerging data and clinical trials for patients with advanced HCC.
Free Registration Required
HCC: Liver Transplant Vs Resection
The Impact of Underlying Cirrhosis on Managing HCC
New Treatment Leaves Liver Cancer Cells in Limbo
Scientists have shown that a mutation in a gene called Arid1b can cause liver cancer. The gene normally protects against cancer by limiting cell growth, but when mutated it allows cells to grow uncontrollably. The researchers have shown that two existing drugs can halt this growth in human cells. This points to a new approach to treating liver cancer
Hepatocellular carcinoma: a review
Chronic liver disease and cirrhosis remain the most important risk factors for the development of HCC of which viral hepatitis and excessive alcohol intake are the leading risk factors worldwide. Importantly, the incidence of HCC will continue to escalate as hepatitis C reaches its maturity and as nonalcoholic steatohepatitis (NASH) and obesity become more prevalent in the United States.
Diabetes, Obesity Linked to Liver Cancer in Study
Rates of liver cancer have steadily climbed alongside rising rates of obesity and diabetes, leading researchers to investigate links among the conditions.
Community Outreach May Reduce the Risk of Liver Cancer
Liver cancer is more common among Asian Americans in part because they are at high risk of HBV infection. One out of 12 Asian Americans carries the virus, accounting for more than half of the cases in the US
Persistent hepatitis C virus (HCV) infection is associated with high incidence of hepatocellular carcinoma (HCC), the most common primary malignancy according to an Theoretical Article published online 7 October 2016; Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis.
10 developments in liver cancer
Discovering links between hepatocellular carcinoma and direct-acting antivirals, exploring risk factors for HCC, conducting clinical trials of new medications for the…
RedHill Announces Initiation of Phase II Study with YELIVA™ in Hepatocellular Carcinoma at the Medical University of South Carolina
MRI bests ultrasound for early detection of HCC - Healio
Magnetic resonance imaging — as opposed to ultrasound — offers a significantly greater chance of detecting hepatocellular carcinoma early, according to a prospective surveillance study published in JAMA Oncology.
Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to Hepatitis C and Non Alcoholic Fatty Liver Disease
In this study NAFLD patients presented with larger tumours that were less likely to be amenable to curative therapy, as compared with HCV patients. Despite this disadvantage, patients with NAFLD had similar overall survival compared to patients with HCV
ILCA Annual Conference Coverage - Conflicting Evidence Surfaces on Anti-HCV Drugs for Liver Cancer
A new generation of drugs has proved highly effective against the hepatitis C virus but there is conflicting evidence about whether the therapies promote cancer recurrence in infected patients with hepatocellular carcinoma who already have responded to curative treatment.
Transplant recipients who resume smoking have shorter survival
Australian risk for HBV-related HCC declined, HCV–HCC risk increased
Minimally-Invasive Surgery Options for Liver Cancer and Liver Tumors
Anti-viral therapy was associated with a reduction in Hep B-related HCC
Liver Cancer is one of eight cancers linked to overweight and obesity
Beyond HCV: Radiopaque Bead Treatment ‘Potential Game-Changer’ for HCC
Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution
These different studies bring no strong evidence for an increased risk of HCC occurrence in "HCC naïve" patients treated by DAA. However, the persistent risk of HCC development strongly justifies HCC screening after viral clearance in patients with HCV related cirrhosis.
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
In this review, clinical studies of systemic chemotherapy for advanced HCC will be summarized and discussed.
Dr. Yasmin Thanavala on targeted therapy for liver cancer
Direct-acting antivirals in hepatitis C do not reduce hepatocellular carcinoma occurrence
Blood-born molecules could predict those who will develop liver cancer
Hepatocellular carcinoma, the most common type of liver cancer, is increasing in incidence in the United States, and infection with the Hepatitis B virus (HBV) causes about 50 percent of cases. However, it can be difficult to identify who is most likely to develop this cancer.
Targeted treatment for liver cancer under way
Does AAV-based gene delivery cause liver cancer? The debate heats up
Liver cancer recurrence may be predictable from protein levels
Treatment options evolve as HCC becomes more common
At the same time, the profile of HCC is changing. Many clinicians matured in an era when viral hepatitis was the primary risk factor for HCC. Newer, more effective therapies can cure hepatitis C (HCV) in most patients, but simply curing a patient of HCV does not completely eliminate the need for HCC surveillance.
Experts will explore links between liver cancer and NAFLD
The emergence of nonalcoholic fatty liver disease (NAFLD) as the most common liver disorder in the U.S. and many other countries has set the stage for a potential increase in liver cancer.
Liver Cancer Found in Hepatitis C Patients on New Antivirals
The study by Dr Brillanti’s team, presented here at the International Liver Congress 2016, suggests that patients with hepatitis C should be closely monitored after treatment with direct-acting antivirals. Two days earlier, a study conducted by a team from the University of Barcelona in Spain suggested the same thing (J Hepatol. Published online April 12, 2016).
Listen: Is liver cancer more common than we think? on Health Report
Medicare beneficiaries with HCC show short survival on Nexavar
Novel Agents on Horizon for Advanced HCC
High rate of cancer recurrence in Hepatitis C patients despite successful virus eradication by direct-acting antiviral therapy
Scientists call for close monitoring of Hepatitis C virus patients prescribed direct-acting antivirals, particularly for those with a history of liver cancer
How Best To Address The Increase In Liver Cancer Deaths
Genetic tests identify 6 types of liver cancer among Japanese patients
Elderly veterans with chronic HCV at increased risk for cirrhosis, HCC
Elderly veterans with hepatitis C virus infection had a higher risk for developing cirrhosis or hepatocellular carcinoma compared with younger patients, according to results from a retrospective cohort study.
Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?
Liver Cancer in Patients Cured of HCV: Less Cirrhosis and Less Fat than Expected
Cancer death rates decline but increase in liver cancer deaths cause for concern
The authors noted that, in the United States, a major contributing factor to liver cancer is hepatitis C virus (HCV) infection. A little more than 20 percent of the most common liver cancers are attributed to HCV infection. Compared with other adults, people born during 1945-1965 have a six times greater risk of HCV infection. CDC recommends all people born duri
Alcohol- vs HCV-related Hepatocellular Carcinoma
Alimentary Pharmacology & Therapeutics, February 17, 2016
Diabetes, High Blood Pressure Increase HCC Risk
JAMA Network | JAMA | Treatment of Liver Cancer
In the United States, the biggest risk factors for HCC are hepatitis C infection, chronic heavy alcohol consumption, and nonalcoholic fatty liver disease related to ...
A Spin Around the Sun
I looked back on the slices of life.
January had my Alpha Feta Protein, AFP tumor marker going back up. Then an MRI showed that the darn thing was growing again.
Piecing Together the Causes and Effects of HCV-Related HCC
The community of patients and practitioners associated with hepatitis C virus has grown accustomed to rapid development and ongoing breakthroughs. However, despite a long history and some new research, the pace of progress in understanding the relationship between HCV and hepatocellular carcinoma remains sluggish.